Johnson & Johnson

Johnson & Johnson

Prix: 240.87

Entreprise et modèle économique

Johnson & Johnson is a global healthcare company that develops and manufactures a wide range of products across three major segments: Pharmaceuticals, Medical Devices, and Consumer Health. Its core products include prescription medications, surgical instruments, and consumer health products such as over-the-counter drugs and personal care items. The company generates revenue primarily from its pharmaceutical segment, which includes treatments for various diseases, followed by medical devices and consumer health products.

Profil d’investissement

Johnson & Johnson presents a balanced investment profile, appealing to investors seeking a combination of growth and dividends. The company has a stable dividend yield, indicating a commitment to returning value to shareholders. Its diversified business segments provide resilience against market fluctuations, making it suitable for medium to long-term investment horizons.

Site officiel

Métriques fondamentales (expérimental)

BPA (TTM) — bénéfice par action des 12 derniers mois, $
8.67 OK
Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
-2.0%
Surprise BPA
0.7% conforme
Volatilité 20 j
1.2% stable
Rendement du dividende
2.3% modéré dernière date ex-dividende: 2026-05-26
Données FMP / FinFeed mises à jour: 2026-06-13
Reco: Acheter Potentiel: 69 Risque: 40 Mis à jour: 2026-06-13 02:53
Comment fonctionne la recommandation
Pourquoi l’IA pense cela:
Stable fundamentals, but recent revenue decline raises concerns.

Suivre dans le portefeuille

Graphique des prix

Recommandation IA Prévision d’analyste Événement calendrier Signal positif Signal négatif Neutre / mise à jour Conserver / informatif B My buy S My sell
Changements de recommandation IA
Date Avant Après Raison
2026-06-10 00:46 Conserver Acheter Strong momentum and solid dividend yield support growth.
2026-05-30 02:42 Acheter Conserver Weak momentum and fundamentals raise uncertainty.
2026-05-22 02:50 Conserver Acheter Stable dividends, but mixed momentum signals present uncertainty.
Prévisions des analystes
Date Analyste Action Objectif Prix alors
2026-05-13 10:04 Leerink Partners Note relevée — → 265 224.26
2026-04-20 12:24 Guggenheim Objectif relevé 244 → 266 232.71
2026-04-15 12:31 Morgan Stanley Objectif relevé 267 → 283 239.66